Disruption of this regulatory process has been implicated in various metabolic disorders, including diabetes, cancers, and heart failure8, and this has prompted investigations into therapeutic interventions targeting PDH in conditions such as nonalcoholic fatty liver disease9 and obesity10. The gene discussed is PDP1; the disease is metabolic disease.